{"disease":{"id":"moderate-to-severe-alzheimer-s-type-dementia","name":"Moderate to Severe Alzheimer's Type Dementia","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":6,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"donepezil","indication_name":"Moderate to Severe Alzheimer's Type Dementia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aricept","generic_name":"DONEPEZIL","company_name":"Eisai","drug_phase":"marketed","molecular_target":"Sigma non-opioid intracellular receptor 1","drug_class":"Cholinesterase Inhibitor","quality_score":75,"revenue":"800","mechanism":"Aricept works by blocking the enzyme that breaks down a key neurotransmitter in the brain, acetylcholine."},{"drug_id":"donepezil-aricept","indication_name":"Moderate to Severe Alzheimer's Type Dementia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Donepezil (Aricept)","company_name":"University of Virginia","drug_phase":"marketed","molecular_target":"Beta-secretase 1, Multidrug resistance protein 1, Acetylcholine receptor subunit epsilon","drug_class":"Acetylcholinesterase Inhibitor","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"aricept","indication_name":"Moderate to Severe Alzheimer's Type Dementia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Aricept","company_name":"Eisai Korea Inc.","drug_phase":"marketed","molecular_target":"Beta-secretase 1, Multidrug resistance protein 1, Acetylcholine receptor subunit epsilon","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"namenda","indication_name":"Moderate to Severe Alzheimer's Type Dementia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Namenda","company_name":"Inova Health Care Services","drug_phase":"marketed","molecular_target":"Solute carrier family 22 member 1, 5-hydroxytryptamine receptor 3A, Acetylcholinesterase","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"memantine","indication_name":"Moderate to Severe Alzheimer's Type Dementia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Namenda","generic_name":"MEMANTINE","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Glutamate NMDA receptor; GRIN1/GRIN2A","drug_class":"N-methyl-D-aspartate Receptor Antagonist","quality_score":60,"revenue":null,"mechanism":"Namenda works by blocking the action of glutamate at the NMDA receptor, reducing excessive neural activity associated with Alzheimer's disease."},{"drug_id":"ebixa","indication_name":"Moderate to Severe Alzheimer's Type Dementia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ebixa","company_name":"Konkuk University Medical Center","drug_phase":"marketed","molecular_target":"Solute carrier family 22 member 1, 5-hydroxytryptamine receptor 3A, Acetylcholinesterase","drug_class":"","quality_score":16,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":6,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}